India Pharma Outlook Team | Tuesday, 30 June 2026
India's Pharma Exports are entering a new phase as drugmakers expand beyond their biggest market, the US, to tap fresh opportunities in Brazil.
India's Pharma Exports to Brazil have grown rapidly over the past two years, making the South American nation the country's second-largest pharmaceutical export destination.
The shift comes as Indian companies look to reduce dependence on traditional markets while increasing exports of high-value medicines such as branded generics, biosimilars, and oncology drugs.
Brazil has become a major growth engine for India's Pharma Exports, with shipments reaching USD 916 million, accounting for nearly 2.94 percent of India's total pharmaceutical exports. If the current growth trend continues, exports to Brazil are expected to cross the USD 1 billion mark by FY2027.
Indian pharmaceutical exports to Brazil have recorded an annual growth rate of nearly 17-18 percent over the last two years. Rising healthcare spending, increasing demand for affordable medicines, and the expansion of Brazil's generic drug market have created new opportunities for Indian drugmakers.
The growing demand has also encouraged companies to move beyond exporting Active Pharmaceutical Ingredients (APIs) and focus on higher-value products, including:
This shift reflects India's broader strategy of exporting more complex and higher-margin pharmaceutical products instead of relying mainly on bulk drug supplies.
Also Read: E-pharmacy in India 2026: Top Apps for Medicine Delivery
While Brazil offers strong growth potential, it remains one of the toughest pharmaceutical markets to enter.
The country's health regulator, ANVISA, follows strict quality and manufacturing standards that are comparable to global regulatory agencies. Drug approvals often take longer, making market entry challenging for companies without strong regulatory capabilities.
Apart from regulatory hurdles, exporters also face:
Despite these challenges, Indian pharmaceutical companies continue to expand their presence by investing in product registrations and building long-term partnerships in the country.
Several leading Indian drugmakers have established a strong footprint in Brazil, including Sun Pharma, Dr. Reddy's Laboratories, Glenmark Pharmaceuticals, and Torrent Pharmaceuticals.
Among them, Torrent Pharmaceuticals has emerged as one of the strongest players. The company entered Brazil in 2003, and the market now contributes nearly 10 percent of its total revenue. Torrent is growing faster than the overall Brazilian pharmaceutical market and currently has 58 drug applications awaiting approval from ANVISA, giving it a strong pipeline for future expansion.
"IQVIA data shows Q4 market growth at 6 percent with Torrent growing at 17 percent," said Sanjay Gupta, Executive Director (International Business) at Torrent Pharmaceuticals.
For India's pharmaceutical industry, Brazil represents more than just another export destination. It highlights a broader export diversification strategy that reduces dependence on the US while opening new revenue streams in regulated international markets.
As global demand for affordable and quality medicines continues to rise, India's Pharma Exports are expected to benefit from stronger demand in emerging markets like Brazil. Companies that can navigate strict regulatory requirements and expand their portfolio of specialty medicines are likely to gain the most from the country's next phase of export growth.
.jpg)
